$BRTX
BioRestorative Therapies, Inc. Stock $brtx

$brtx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415067511 Filed on November 23, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$96.12K	$80.00K	$159.9K
YoY Change	-39.9%		127844.0%
Cost Of Revenue	$50.92K	$110.0K	$66.12K
YoY Change	-22.98%		661050.0%
Gross Profit	$45.20K	-$30.00K	$93.82K
YoY Change	-51.82%		81478.26%
Gross Profit Margin	47.02%	-37.5%	58.66%
Selling, General & Admin	$920.0K	$940.0K	$700.0K
YoY Change	31.43%
% of Gross Profit	2035.35%		746.15%
Research & Development	$615.6K	$350.0K	$290.7K
YoY Change	111.78%		-29.94%
% of Gross Profit	1362.02%		309.87%
Depreciation & Amortization	$60.00K	$30.00K	$20.00K
YoY Change	200.0%
% of Gross Profit	132.74%		21.32%
Operating Expenses	$1.535M	$1.290M	$989.8K
YoY Change	55.09%		-12.34%
Operating Profit	-$1.490M	-$1.320M	-$896.0K
YoY Change	66.28%		-20.64%
Interest Expense	$80.65K	-$150.0K	$74.78K
YoY Change	7.85%		33.45%
% of Operating Profit
Other Income/Expense, Net	-$133.9K	-$20.00K	-$204.4K
YoY Change	-34.49%		17.49%
Pretax Income	-$1.620M	-$1.480M	-$1.100M
YoY Change	47.27%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.624M	-$1.480M	-$1.100M
YoY Change	47.56%		-15.55%
Net Earnings / Revenue	-1689.35%	-1850.0%	-688.08%
Basic Earnings Per Share
Diluted Earnings Per Share	-$572.4K	-$925.0K	-$814.8K
COMMON SHARES
Basic Shares Outstanding	2.826M shares	31.46M shares	26.80M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.00K	$90.00K	$370.0K
YoY Change	-97.3%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$370.0K	$20.00K	$30.00K
YoY Change	1133.33%
Inventory	$2.492K	$1.945K	$17.39K
Prepaid Expenses
Receivables		$0.00	$0.00
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$385.0K	$114.3K	$421.5K
YoY Change	-8.66%	-52.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$662.5K	$493.9K	$73.58K
YoY Change	800.44%	1288.48%
Goodwill
YoY Change
Intangibles	$1.057M	$1.038M	$1.055M
YoY Change	0.22%	-6.3%
Long-Term Investments
YoY Change
Other Assets	$50.00K	$50.00K	$50.00K
YoY Change	0.0%
Total Long-Term Assets	$1.766M	$1.577M	$1.175M
YoY Change	50.33%	38.0%
TOTAL ASSETS
Total Short-Term Assets	$385.0K	$114.3K	$421.5K
Total Long-Term Assets	$1.766M	$1.577M	$1.175M
Total Assets	$2.151M	$1.692M	$1.596M
YoY Change	34.75%	22.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.110M	$1.112M	$774.1K
YoY Change	172.62%	-12.45%
Accrued Expenses	$1.969M	$1.467M	$1.220M
YoY Change	61.38%	24.63%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.240M	$5.690M	$5.170M
YoY Change	-76.02%
Total Short-Term Liabilities	$5.465M	$8.525M	$7.428M
YoY Change	-26.42%	13.63%
LONG-TERM LIABILITIES
Long-Term Debt	$420.0K	$50.00K	$620.0K
YoY Change	-32.26%
Other Long-Term Liabilities	$40.00K	$10.00K	$0.00
YoY Change
Total Long-Term Liabilities	$460.0K	$60.00K	$620.0K
YoY Change	-25.81%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.465M	$8.525M	$7.428M
Total Long-Term Liabilities	$460.0K	$60.00K	$620.0K
Total Liabilities	$5.927M	$8.580M	$8.054M
YoY Change	-26.41%	6.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.20M	-$25.40M
YoY Change		28.2%
Common Stock	$2.882K	$1.726K	$31.58K
YoY Change	-90.87%	-91.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$32.00K	$32.00K	$32.00K
YoY Change	0.0%	0.0%
Treasury Stock Shares	27.93K shares	27.93K shares	558.6K shares
Shareholders Equity	-$3.776M	-$6.888M	-$6.458M
YoY Change
Total Liabilities & Shareholders Equity	$2.151M	$1.692M	$1.596M
YoY Change	34.75%	22.34%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$1.624M	-$1.480M	-$1.100M
YoY Change	47.56%		-15.55%
Depreciation, Depletion And Amortization	$60.00K	$30.00K	$20.00K
YoY Change	200.0%
Cash From Operating Activities	-$590.0K	-$640.0K	-$830.0K
YoY Change	-28.92%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$170.0K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$210.0K	-$170.0K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	790.0K	520.0K	1.150M
YoY Change	-31.3%
NET CHANGE
Cash From Operating Activities	-590.0K	-640.0K	-830.0K
Cash From Investing Activities	-210.0K	-170.0K	0.000
Cash From Financing Activities	790.0K	520.0K	1.150M
Net Change In Cash	-10.00K	-290.0K	320.0K
YoY Change	-103.12%
FREE CASH FLOW
Cash From Operating Activities	-$590.0K	-$640.0K	-$830.0K
Capital Expenditures	-$210.0K	-$170.0K	$0.00
Free Cash Flow	-$380.0K	-$470.0K	-$830.0K
YoY Change	-54.22%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q3	us-gaap	Cash Cash	12793	USD
CY2014Q4	us-gaap	Cash Cash	91798	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	2492	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	1945	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	28546	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20570	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	384998	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	114313	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	662502	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493856	USD
CY2015Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1057465	USD
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1037732	USD
CY2015Q3	us-gaap	Assets Assets	2150865	USD
CY2014Q4	us-gaap	Assets Assets	1691801	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2110257	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1111879	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1969286	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1466506	USD
CY2015Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	40151	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	94026	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	1244202	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	5688239	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5465423	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8524999	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	39420	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	5195	USD
CY2015Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	422182	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	50000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	5927025	USD
CY2014Q4	us-gaap	Liabilities Liabilities	8580194	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	2882	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	1726	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26457238	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18541907	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-30204280	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25400026	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	360466	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	32000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-3776160	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6888393	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2150865	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1691801	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	101527	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164349	USD
CY2015Q3	us-gaap	Security Deposit SecurityDeposit	45900	USD
CY2014Q4	us-gaap	Security Deposit SecurityDeposit	45900	USD
CY2015Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	341167	USD
CY2014Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	USD
CY2014Q3	us-gaap	Revenues Revenues	159930	USD
CY2015Q3	us-gaap	Revenues Revenues	96122	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	66115	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	50921	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	93815	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	45201	USD
CY2014Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	41840	USD
CY2015Q3	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	40412	USD
CY2014Q3	us-gaap	Professional Fees ProfessionalFees	154492	USD
CY2015Q3	us-gaap	Professional Fees ProfessionalFees	282536	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	290707	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	615648	USD
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	502783	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	596515	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	989822	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	1535111	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-896007	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1489910	USD
CY2014Q3	us-gaap	Interest Expense InterestExpense	74780	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	80647	USD
CY2014Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	137167	USD
CY2015Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	37063	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2014Q3	brtx	Warrant Modification Expense WarrantModificationExpense	0	USD
CY2015Q3	brtx	Warrant Modification Expense WarrantModificationExpense	16215	USD
CY2014Q3	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	7500	USD
CY2015Q3	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-204447	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-133925	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-1100454	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1623835	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.81
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.57
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1352188	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2829416	shares
	us-gaap	Revenues Revenues	429788	USD
	us-gaap	Revenues Revenues	336246	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	201998	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	108541	USD
	us-gaap	Gross Profit GrossProfit	227790	USD
	us-gaap	Gross Profit GrossProfit	227705	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	134440	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	89169	USD
	us-gaap	Professional Fees ProfessionalFees	786596	USD
	us-gaap	Professional Fees ProfessionalFees	979255	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1687415	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4378680	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3605912	USD
	us-gaap	Interest Expense InterestExpense	205383	USD
	us-gaap	Interest Expense InterestExpense	220301	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	177947	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	381602	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-26029	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-49094	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	16215	USD
	brtx	Warrant Modification Expense WarrantModificationExpense	30128	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	0	USD
	brtx	Gain Loss Related To Settlement Of Note And Payables GainLossRelatedToSettlementOfNoteAndPayables	183768	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-425574	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-497357	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4804254	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4103269	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.51
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2275223	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1170139	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1361000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	201801	USD
	brtx	Shares Issued In Satisfaction Of Accrued Interest SharesIssuedInSatisfactionOfAccruedInterest	8481	USD
	brtx	Stocks And Warrants Issued During Period Value In Connection With Settlement Agreement StocksAndWarrantsIssuedDuringPeriodValueInConnectionWithSettlementAgreement	152000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	82042	USD
	brtx	Stocks And Warrants Issued During Period Value In Exchange Of Debt StocksAndWarrantsIssuedDuringPeriodValueInExchangeOfDebt	5142065	USD
	brtx	Warrant Modification Charge WarrantModificationCharge	22115	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	10690	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	141647	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	794646	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73889	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	150646	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1009	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1075499	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	936293	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-580	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	547	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-11629	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7976	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-488416	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	629944	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	445749	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	842545	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1509676	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2736250	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2593593	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2068004	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1526	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	980	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-546	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-435466	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	670000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	950015	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	53000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	35539	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	401575	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	60529	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	280075	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	80000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	2095001	USD
	brtx	Proceeds From Issuance Of Common Stock And Warrants Net ProceedsFromIssuanceOfCommonStockAndWarrantsNet	1361000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2767011	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2424465	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	172872	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-79005	USD
CY2013Q4	us-gaap	Cash Cash	201098	USD
CY2014Q3	us-gaap	Cash Cash	373970	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	154662	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-62822	USD
	brtx	Payments To License Maintenance Costs PaymentsToLicenseMaintenanceCosts	75000	USD
	brtx	Payments To License Maintenance Costs PaymentsToLicenseMaintenanceCosts	0	USD
	us-gaap	Accretion Expense AccretionExpense	47626	USD
	us-gaap	Accretion Expense AccretionExpense	0	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	8050	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	brtx	Warrant Modification Extension Expense WarrantModificationExtensionExpense	16215	USD
	brtx	Warrant Modification Extension Expense WarrantModificationExtensionExpense	30128	USD
CY2015Q3	brtx	Stockholders Equity Note Changes In Capital Structure Retroactive Impact Shares StockholdersEquityNoteChangesInCapitalStructureRetroactiveImpactShares	200000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2015Q3	brtx	Working Capital Net WorkingCapitalNet	5080425	USD
	brtx	Revenue Received RevenueReceived	688891	USD
	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	587364	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	830847	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1773095	shares
CY2015Q3	brtx	Credit Card Payable Current CreditCardPayableCurrent	3171	USD
CY2014Q4	brtx	Credit Card Payable Current CreditCardPayableCurrent	4739	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	978255	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	679277	USD
CY2015Q3	us-gaap	Accrued Rent Current AccruedRentCurrent	43753	USD
CY2014Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	0	USD
CY2015Q3	brtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	466175	USD
CY2014Q4	brtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	292395	USD
CY2015Q3	brtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	421432	USD
CY2014Q4	brtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	315294	USD
CY2015Q3	brtx	Accrued Purchase Of Property And Equipment AccruedPurchaseOfPropertyAndEquipment	0	USD
CY2014Q4	brtx	Accrued Purchase Of Property And Equipment AccruedPurchaseOfPropertyAndEquipment	174801	USD
CY2015Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	56500	USD
CY2014Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	5738239	USD
CY2015Q3	us-gaap	Notes Payable NotesPayable	1666384	USD
	brtx	Note Payable Principal Issued NotePayablePrincipalIssued	1103018	USD
	us-gaap	Repayments Of Other Short Term Debt RepaymentsOfOtherShortTermDebt	5000	USD
	brtx	Exchanges For Equity ExchangesForEquity	5020478	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	188333	USD
	brtx	Recognition Of Debt Discount RecognitionOfDebtDiscount	186635	USD
CY2015Q1	brtx	Class Of Warrant Or Rightst Expiration Date ClassOfWarrantOrRightstExpirationDate	2015-12-31
CY2015Q3	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	0	USD
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	33000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.16
	us-gaap	Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued	27698	shares
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	141647	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	97000	USD
CY2014Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	brtx	Class Of Warrant Or Righst Expiration Date ClassOfWarrantOrRighstExpirationDate	2017-12-31
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5000	shares
CY2015Q3	brtx	Warrant Or Right Expense Or Revenue Recognized WarrantOrRightExpenseOrRevenueRecognized	6215	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.52
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.60
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.80
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	779200	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	66000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	35000	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	810200	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	476160	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.18
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	14.94
	brtx	Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M18D
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.80
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.34
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	66501	USD
CY2014Q4	brtx	Debt Instrument Unamortized Debt Discount Current Portion DebtInstrumentUnamortizedDebtDiscountCurrentPortion	113257	USD
CY2015Q3	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	7818	USD
CY2014Q4	brtx	Debt Instrument Unamortized Debt Discount Noncurrent Portion DebtInstrumentUnamortizedDebtDiscountNoncurrentPortion	0	USD
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2882200	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1725596	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2854268	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1697664	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	27932	shares
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	27932	shares
	brtx	Share Rounding Dueto Reverse Stock Value Split ShareRoundingDuetoReverseStockValueSplit	0	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	USD
	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	45900	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Concentrations and Credit Risk</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and nine months ended September 30, 2015. See Revenue Recognition Research and Development Agreements below.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2013Q4	us-gaap	Loss Contingency Allegations LossContingencyAllegations	The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	65000	USD
CY2015Q3	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	75000	USD
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2015-10-30
	us-gaap	Debt Instrument Convertible Terms Of Conversion Feature DebtInstrumentConvertibleTermsOfConversionFeature	July 2015 and March 2016
CY2015Q3	brtx	Share Based Compensation Exercise Price Range Number Of Outstanding Warrants ShareBasedCompensationExercisePriceRangeNumberOfOutstandingWarrants	792334	shares
CY2015Q3	brtx	Share Based Compensation Exercise Price Range Number Of Exercisable Warrants ShareBasedCompensationExercisePriceRangeNumberOfExercisableWarrants	757334	shares
	brtx	Share Based Compensations Exercise Price Range Exercisable Warrant Weighted Average Remaining Contractual Term ShareBasedCompensationsExercisePriceRangeExercisableWarrantWeightedAverageRemainingContractualTerm	P3Y8M12D
CY2015Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	810200	shares
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2015Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	476160	shares
	brtx	Warrant Or Right Expense Or Revenue Recognized WarrantOrRightExpenseOrRevenueRecognized	16215	USD
	us-gaap	Interest Paid InterestPaid	59603	USD
	us-gaap	Interest Paid InterestPaid	76060	USD
	brtx	Conversion Of Notes Payable And Accruedinterest In To Common Stock ConversionOfNotesPayableAndAccruedinterestInToCommonStock	201801	USD
	brtx	Conversion Of Notes Payable And Accruedinterest In To Common Stock ConversionOfNotesPayableAndAccruedinterestInToCommonStock	327946	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	0	USD
	brtx	Reclassification Of Accrued Interest In Connection With Note Payable Issuance ReclassificationOfAccruedInterestInConnectionWithNotePayableIssuance	73058	USD
	us-gaap	Debt Instrument Convertible Beneficial Conversion Feature DebtInstrumentConvertibleBeneficialConversionFeature	86563	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	333117	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	brtx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	96441	USD
	brtx	Accrued Purchases Of Property And Equipment AccruedPurchasesOfPropertyAndEquipment	0	USD
	brtx	Indebtedness Satisfied Via Legal Settlement IndebtednessSatisfiedViaLegalSettlement	0	USD
	brtx	Indebtedness Satisfied Via Legal Settlement IndebtednessSatisfiedViaLegalSettlement	5000	USD
	brtx	Conversion Of Debt Amount Converted ConversionOfDebtAmountConverted	65000	USD
CY2015Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company, the Company implemented a 1-for-20 reverse split
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	74923	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-19650	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	3919	USD
	brtx	Warrants To Purchase Of Common Stock WarrantsToPurchaseOfCommonStock	24500	shares
CY2015Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.00
CY2015Q3	brtx	Options To Purchase Of Common Stock OptionsToPurchaseOfCommonStock	505250	shares

Files In Submission

Name	View Source	Status
0001144204-15-067511-index-headers.html	Edgar Link	pending
0001144204-15-067511-index.html	Edgar Link	pending
0001144204-15-067511.txt	Edgar Link	pending
0001144204-15-067511-xbrl.zip	Edgar Link	pending
brtx-20150930.xml	Edgar Link	completed
brtx-20150930.xsd	Edgar Link	pending
brtx-20150930_cal.xml	Edgar Link	unprocessable
brtx-20150930_def.xml	Edgar Link	unprocessable
brtx-20150930_lab.xml	Edgar Link	unprocessable
brtx-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423267_10q.htm	Edgar Link	pending
v423267_ex31-1.htm	Edgar Link	pending
v423267_ex31-2.htm	Edgar Link	pending
v423267_ex32.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BRTX
BioRestorative Therapies, Inc. Stock $brtx

2015 Q3 Form 10-Q Financial Statement

#000114420415067511 Filed on November 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX BioRestorative Therapies, Inc. Stock $brtx

2015 Q3 Form 10-Q Financial Statement

#000114420415067511 Filed on November 23, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BRTX
BioRestorative Therapies, Inc. Stock $brtx